The Tempus AI story
What drives Tempus AI, what its price assumes and what could change the story, written from its own filings.
- Oncology drives demand. In the quarter to June 2026, Oncology Diagnostics volume grew 31% year over year and molecular residual disease test volume reached 9,000, compared with 6,500 in the preceding quarter.
- Profit needs context. Net income of $5.6 million in the quarter to June 2026 included $98.5 million in unrealized gains on marketable securities, while Adjusted EBITDA was $8.0 million.
- Cancer monitoring expands. The agreement to acquire Personalis for $16.25 per share would bring its NeXT Personal molecular residual disease technology into Tempus’ diagnostic platform.
